SCHEMBL30714749

SCHEMBL30714749

Cn1nc2ccc(OCc3cccnc3C(F)(F)F)cc2c1C(=O)NC(C)(CO)CO

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 1/20 0.35
MCHR1 Q99705 5/20 0.33
CD38 P28907 1/20 0.33
DGAT2 Q96PD7 1/20 0.33
KLKB1 P03952 1/20 0.33
GRM2 Q14416 1/20 0.33
SSTR4 P31391 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
GCK P35557 1/20 0.32
MAPT P10636 4/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.32
ANO1 Q5XXA6 1/20 0.32
HSD17B13 Q7Z5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26868368 0.94 OPRL1 (0.34) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL30714582 0.93 CNR2 (0.37) OPRL1MCHR1CD38DGAT2KLKB1
SCHEMBL30714598 0.90 OPRL1 (0.35) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL30714600 0.89 TYK2 (0.38) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL30714583 0.88 OPRL1 (0.33) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL26696066 0.88 OPRL1 (0.33) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL31539903 0.87 OPRL1 (0.34) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL26696085 0.86 NPC1 (0.37) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL30714557 0.86 NPC1 (0.37) OPRL1MCHR1CD38KLKB1GRM2
SCHEMBL30714722 0.86 KDM4C (0.39) OPRL1GRM2KDM4CMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 OPRL1 112/4885MCHR1 1891/4885CD38 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.